Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Britain Courts Anthropic Amid US Defense Department Dispute 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
WALTHAM, Mass., Sept. 01, 2016 -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that company management will participate in an analyst-led fireside chat at the Morgan Stanley Global Healthcare Conference on Monday, September 12, 2016 at 10:30 a.m. EDT.
A live audio webcast of the discussion will be accessible through the Investors section of the company’s website at www.amagpharma.com and will be archived for 30 days.
About AMAG
AMAG is a biopharmaceutical company focused on developing and delivering important therapeutics, conducting clinical research in areas of unmet need and creating education and support programs for the patients and families we serve. Our products support the health of patients in the areas of maternal health, anemia management and cancer supportive care. Through CBR®, we also help families to preserve newborn stem cells, which are used today in transplant medicine for certain cancers and blood, immune and metabolic disorders, and have the potential to play a valuable role in the ongoing development of regenerative medicine. For additional company information, please visit www.amagpharma.com.
AMAG Pharmaceuticals® is a registered trademark of AMAG Pharmaceuticals, Inc. and CBR® is a registered trademark of CBR Systems, Inc.
AMAG Pharmaceuticals Contact: Linda Lennox Vice President, Investor Relations 617-498-2846
